Johnson & Johnson (JNJ) raised its full-year outlook on Wednesday after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses.
The healthcare products conglomerate now anticipates adjusted earnings of $11.60 to $11.75 per share for 2026, up from its previous projection of $11.45 to $11.65. Sales are pegged between $100.8 billion and $101.4 billion, compared with the prior guidance of $100.3 billion to $101.3 billion.
The consensus on FactSet is for non-GAAP EPS of $11.59 and sales of $101.06 billion for the year.
"Johnson & Johnson delivered strong second-quarter results," Chief Executive Joaquin Duato said in a statement. "With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our company's 140-year history."
For the quarter ended June 28, Johnson & Johnson's adjusted EPS increased to $2.90 from $2.77 last year, topping the Street's view for $2.85. Sales improved 6.6% to $25.31 billion, surpassing the average analyst estimate of $25.02 billion.
Innovative medicine sales grew 7.8% to $16.38 billion. Operational revenue moved 6.8% higher, driven by the group's oncology products, including blood cancer therapy Darzalex and multiple myeloma treatment Carvykti, as well as immunology product Tremfya. Divestitures negatively impacted operational sales by 10 basis points, according to the company.
Medtech revenue advanced 4.5% to $8.93 billion. Operational sales were up 3.6%, buoyed by the firm's wound closure, biosurgery and electrophysiology products, among others, it said.
Revenue in the US increased to $14.53 billion from $13.54 billion in the year-ago period, while international sales gained 5.7%.



